Earlier access to medicines and medical technologies and the MMDR - - PowerPoint PPT Presentation

Earlier access to medicines and medical technologies and the MMDR

Dr John Skerritt Health Products Regulation Group Commonwealth Department of Health ARCS Conference, Sydney 24 August 2017

Overarching principles for regulation as endorsed by Government

• The Australian Government retains responsibility for approving the

inclusion of therapeutic goods in the ARTG – however need to make much greater use of overseas evaluations

• Need to introduce greater flexibility in approval pathways

– to enable earlier access to therapeutics without compromising safety, efficacy and quality

• TGA could more appropriately align level regulation with the actual

risk posed by the products in certain areas

Prescription Medicines

3

Expedited pathways for prescription medicines

• Priority Review of a complete data dossier in certain circumstances
• Provisional Approval on the basis of early data on safety and efficacy,

where the immediate availability of the medicine outweighs the risk that additional data is still required

• Some of eligibility criteria for Priority Review and Provisional Approval similar:

– serious condition – major therapeutic advance – comparison against existing therapeutic goods

• Others are quite different - eligibility for:

– Priority Review is based on ‘substantial evidence’ – Provisional Approval will be based on ‘promising evidence from early clinical data’

4

Designation process

Applicable to Priority Review, Provisional Approval and Orphan drugs

Pre- designation notification/ meeting Designation application Submission and acceptance Designation decision

weeks 2 weeks 12 weeks 6-7 months

Assessment

• f designation

application

• Against

relevant eligibility criteria

11 weeks 6 weeks

Dossier submission

5

Priority Review – now in place

• New and flexible business processes for NCEs/ EOIs

– First and second round assessment will be condensed across 90 days and no first round assessment report – Delegates overview, expert advice, decision planned for the last 60 days

• Designations lapse if a submission is not provided within six months -

sponsors will be able to seek internal review of the designation decision

• We will publish priority designations on our website – two designations

already granted

• Target of 150 working days consistent internationally
• Pathway provides full registration in the ARTG

6

Provisional pathway designation

• To be implemented from Q1 2018, subject to passage of legislation
• Provisional review pathway designations will be published by TGA

– Negative designation decisions will be appealable by sponsor (only)

• Early clinical data may be based on surrogate endpoints rather than

Phase III trials – Rolling submissions of clinical data during review would be negotiated on a case-by-case basis

• Review timeframes will be standard 255 working days maximum but

every effort will be made to complete reviews faster

7

Provisional Registration

• Registration granted for a specified period

– proposed to be 2 years with maximum of 2 extensions

• The registration decision will take into account whether:

– there is sufficient evidence that the benefit-risk balance is positive – there is promising evidence that early availability of the medicine will provide a significant benefit to Australian patients with unmet clinical needs – sponsor has demonstrated capacity to submit comprehensive clinical data

• n efficacy and safety within the timeframes of provisional registration
• Sponsors may be able to obtain full registration when enough

confirmatory data provided

8

Overview of Provisional Approval pathway

1. Designation process 2. Pre-market registration process 3. Provisional registration period 4. Transition to fully registered if data allows

3-6 months pre-dossier As quickly as possible (max. 255 working days) 2 years (with the possibility of 2 extensions) As quickly as possible (max. 255 working days)

9

Medical Devices

10

The regulatory system

Device Classification determines minimum Conformity Assessment requirements

Risk based classification system Conformity Assessment (CA) by EU body or TGA

Essential Principles, Manufacturing requirements Some applications subject to audit if underwent EU CA

Inclusion in the Australian Register of Therapeutic Goods

Expedited review for certain ‘novel’ devices

• We have consulted on criteria for expedited evaluation
• Will designate particular devices for priority review in under 6 weeks

– if eligible, the sponsor must submit application within 3 months

• Our criteria are similar, but broader than FDA criteria

– TGA proposes to include devices that can prevent diseases and conditions – include “seriously debilitating” not just “irreversibly debilitating” conditions

• Rejection by a foreign regulator and failure to continue meeting

eligibility criteria can result in loss of status

• Impacts on other assessments will need to be managed

Expedited review for certain ‘novel’ devices

• A ‘front-of-queue’ approach, with normal assessment requirements:

– must still comply with Essential Principles etc. – compliance with Clinical Evidence Guidelines is critical

• Criteria focused on health outcomes

– device prevents, diagnoses or treats a life threatening or seriously debilitating disease or condition – addresses an unmet clinical need in Australian patients – “breakthrough” technologies

• Implementation scheduled for January 2018

13

Clinical evidence requirements

• Evidence requirements for expedited pathway same as for other devices
• Clinical data can be generated in Australia or overseas
• Detailed guidance document developed for manufacturers on what constitutes

clinical evidence and the process of clinical data generation and evaluation

• Specific guidance on

– Total and partial joint prostheses – Cardiovascular devices (patency or functional flow) – Implantable pulse generators – Heart valve prostheses – Supportive meshes, patches and tissue adhesives – Implantable medical devices in the MRI environment

14

Enhanced postmarket monitoring

• Better integration and timely analysis of datasets

– Enhanced safety signal detection – Prescription Sequence Symmetry analysis – Linking datasets – e.g. PBS, MBS and hospitals, 45 & Up – Analytics regarding unapproved goods notifications

• Adverse Event Management IT System

– to receive adverse event reports online – Disproportionality Analysis Report and an Electronic Data Interchange

• Enhanced collaboration with overseas Regulatory

Authorities on safety information

15

Specific initiatives for medicines

• Black triangle” scheme to alert practitioners and consumers

– that a drug is newly registered and to encourage reporting of adverse events

• Pharmacovigilance inspection scheme

– Following on from a pilot scheme to audit sponsor obligations

• RMP Compliance Monitoring Program

– Better tools to monitor sponsor’s compliance with Risk Management Plans – RMP requirements published on the TGA website

• Revision of Product Information (PI) templates

– to put information relevant to health practitioners front and centre

16

Medical device postmarket monitoring

For higher risk devices: an AIMD, Class III or implantable Class IIb device Three consecutive annual reports to the TGA required

Adverse event reporting

Environmental scanning (confidential advice from other regulators and review of medical literature, regulatory news, media and

• ther sources)

Options for establishment of registries for high-risk implantable devices still to be considered by Government

Relationship to reimbursement ?

• Reimbursement was outside the terms of reference of the MMDR

– We are well aware that for high cost medicines and devices, “early access” involves government reimbursement decisions – Public Hospital availability of products determined separately

• TGA is working closely with the Health Benefits Group

– On better process alignment for applications, greater use of common information, sharing of clinical expertise – To expand parallel processing and parallel TGA/PBAC review of certain new prescription medicines submissions – My colleague, Andrew Stuart can speak to other policy work

18